P

Pierrel SpA
MIL:PRL

Watchlist Manager
Pierrel SpA
MIL:PRL
Watchlist
Price: 1.745 EUR Market Closed
Market Cap: 95.9m EUR

Relative Value

There is not enough data to reliably calculate the relative value of PRL.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PRL Relative Value
Base Case
Not Available
P
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
2.9
Median 5Y
7.3
Industry
2.7
Forward
3.1
vs History
vs Industry
Median 3Y
30.6
Median 5Y
70.1
Industry
21.5
Forward
144
vs History
vs Industry
Median 3Y
12.2
Median 5Y
23.1
Industry
16.7
vs History
vs Industry
Median 3Y
30.1
Median 5Y
30.1
Industry
23
vs History
vs Industry
Median 3Y
3.7
Median 5Y
7.2
Industry
2.3
vs History
vs Industry
Median 3Y
3.4
Median 5Y
8.2
Industry
2.9
Forward
3.7
vs History
vs Industry
Median 3Y
4.8
Median 5Y
11.6
Industry
5.6
vs History
vs Industry
Median 3Y
17.6
Median 5Y
45.5
Industry
13.2
Forward
16.3
vs History
vs Industry
Median 3Y
31.7
Median 5Y
76.3
Industry
16.6
Forward
30.9
vs History
vs Industry
Median 3Y
14.3
Median 5Y
25.8
Industry
15.8
vs History
vs Industry
Median 3Y
-34
Median 5Y
-34
Industry
19
vs History
vs Industry
Median 3Y
1.9
Median 5Y
3.6
Industry
2

Multiples Across Competitors

PRL Competitors Multiples
Pierrel SpA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IT
Pierrel SpA
MIL:PRL
95.9m EUR 2.9 30.6 17.6 31.7
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.4 37.1 39.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
499.6B USD 5.4 19.9 16.3 21.1
CH
Roche Holding AG
SIX:ROG
262.5B CHF 4.3 27.8 11.9 13.9
UK
AstraZeneca PLC
LSE:AZN
212B GBP 4.9 30.5 108.5 158.8
CH
Novartis AG
SIX:NOVN
211.3B CHF 4.8 18.6 11.8 15.2
US
Merck & Co Inc
NYSE:MRK
265.6B USD 4.1 14 9.9 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.7 14.2 9.9 11.5
IE
Endo International PLC
LSE:0Y5F
212.8B USD 91.8 -72.8 337 845
US
Pfizer Inc
NYSE:PFE
142.7B USD 2.3 14.5 7.4 10.1
P/E Multiple
Earnings Growth PEG
IT
P
Pierrel SpA
MIL:PRL
Average P/E: 25
30.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.4
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.5
37%
0.8
CH
Novartis AG
SIX:NOVN
18.6
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.2
3%
4.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -72.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IT
P
Pierrel SpA
MIL:PRL
Average EV/EBITDA: 401.2
17.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.1
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.9
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.5
10%
10.9
CH
Novartis AG
SIX:NOVN
11.8
6%
2
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
1%
9.9
IE
E
Endo International PLC
LSE:0Y5F
337
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IT
P
Pierrel SpA
MIL:PRL
Average EV/EBIT: 1 714.7
31.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.9
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.8
23%
6.9
CH
Novartis AG
SIX:NOVN
15.2
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
845
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
7%
1.4